Related Experiment Video
Updated: Aug 24, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Cancer information overload may be a crucial determinant of adjuvant aromatase inhibitor adherence
1Presidential Medical Unit, Psychiatry Outpatient Clinic, Ankara, Turkey. drpinareraslan@gmail.com.
Objective:
Medication non-adherence is the leading preventable cause of death among cancer patients. We aimed at investigating whether an online search on cancer treatments creates information overload and to determine the effect of online search on treatment adherence in postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor (AI) treatment.
Patients And Methods:
A total of 103 patients completed the demographic and medical information form, Cancer Information Overload (CIO) scale, Hospital Anxiety Depression Scale (HADS), and Modified Medication Adherence Questionnaire (MAQ).
Results:
More than half of the patients (n=55, 53.4%) performed an additional online search on BC treatment. Median HADS-Anxiety scores, HADS-Depression scores, CIO scores, and percentage of patients with a low MAQ status were 10.00 (7.00-13.00) and 4.00 (3.00-6.75) (p<0.001), 11.00 (6.00-14.00) and 4.00 (2.00-6.00) (p<0.001), 24.00 (17.00-28.00) and 12.00 (10.00-15.00) (p<0.001), and 63.6% (n=35) and 39.6% (n=19) (p=0.018) for the searcher and non-searcher groups, respectively. Co-morbidity(s) (OR 2.407, 95% CI 1.017-5.700, p=0.046) and CIO score (OR 1.126, 95% CI 1.006-1.259, p=0.039) were independent predictive factors of a low MAQ score.
Conclusions:
CIO is one of the main determinants of non-adherence to adjuvant AI treatment. An additional online search on cancer treatment may negatively contribute to patients' CIO, depression, and anxiety levels and does not seem to be beneficial for treatment adherence.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...

